In-vitro and preclinical theragnostic studies based on novel p-Tau monoclonal antibody for tauopathies
Marta Aramburu Núñez, Lara García-Varela, Antía Custodia, Noemí Gómez-Lado, Mónica Castro-Mosquera, Mariña Rodríguez-Arrizabalaga, Manuel Debasa-Mouce, Juan Manuel Pías-Peleteiro, José Manuel Aldrey, Daniel Romaus-Sanjurjo, Alberto Ouro, Pablo Aguiar, Tomás Sobrino · FENS Forum 2024
Tauopathies are leading cause of loss of autonomy in the elderly, implying a progressive cognitive decline. There is not an effective treatment early diagnosis of tauopathies. We propose an in-vitro and theragnostic approach by using a novel phosphorylated Tau(p-Tau) monoclonal antibody(mAb) responsible for tau self-aggregation and regulation.A diagnostic Sandwich ELISA kit was developed and tested in 89 cerebrospinal fluid (CSF) samples of mild cognitive impairment (MCI) and Alzheimer’s disease (AD) patients for detection of p-Tau.The proof of concept study reported specific signals above the
ePoster · Neuroscience